外泌体在肿瘤精准诊断与治疗中的研究进展

doi:10.3969/j.issn.1007-2861.2017.02.003

摘要/Abstract

摘要：

外泌体是一种细胞分泌的具有双层脂质膜结构的纳米级小囊泡, 几乎所有类型的细胞均可分泌外泌体. 外泌体携带核酸和蛋白质等多种具有生物活性的内容物, 不但在细胞间信息交流和信号转导的过程中起着重要作用, 而且参与了人体内各种病理生理过程. 肿瘤来源的外泌体参与调控肿瘤的生长发展和侵袭转移等过程. 外泌体在肿瘤的早期诊断、预后判断以及作为治疗工具方面的探索已经成为研究热点. 对外泌体在肿瘤的发生发展、转移侵袭以及在肿瘤精准诊断与个体化治疗方面的进展作一综述.

关键词: 治疗, 肿瘤, 精准诊断, 外泌体

Abstract:

Exosomes are nanoscale vesicle with a double lipid membrane structure, and can be secreted by almost all types of cells. Exosomes can carry nucleic acids and proteins, and play important roles in a variety of physiological and pathological processes especially in cell communication and signal transduction. Tumor cell-derived exosomes have been proved to be involved in the regulation of tumor growth, invasion and metastasis process. Exosomes’ roles in the early diagnosis, prognosis prediction and therapeutics have been a hot topic. This review summarizes the role of exosomes in the development and metastasis of cancer, and its potential function in the individually precise treatment.

Key words: precision diagnosis, treatment, tumor, exosome

胡牧仁1, 陈婷2, 杨长青3, 葛步军1. 外泌体在肿瘤精准诊断与治疗中的研究进展[J]. 上海大学学报(自然科学版), 2017, 23(2): 161-168.

HU Muren1, CHEN Ting2, YANG Changqing3, GE Bujun1. Exosomes in the precision diagnosis and treatment of cancer[J]. Journal of Shanghai University（Natural Science Edition）, 2017, 23(2): 161-168.

参考文献

[1] Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine [J]. The New England Journal of Medicine, 2012, 366(6): 489-491.
[2] Hugen C M, Zainfeld D E, Goldkorn A. Circulating tumor cells in genitourinary malignancies: an evolving path to precision medicine [J]. Frontiers in Oncology, 2017, 7: 1-6.

[3] Schmidt C. Metabolomics takes its place as latest up-and-coming “omic” science [J]. Journal of the National Cancer Institute, 2004, 96(10): 732-734.
[4] Manterola L, Guruceaga E, P´erez-Larraya J G, et al. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool [J]. Neuro-Oncology, 2014, 16(4): 520-527.
[5] Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy [J]. Nature Medicine, 2012, 18(12): 1835-1840.
[6] Johnstone R M, Adam M, Hammond J R, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes) [J]. Journal of Biological Chemistry, 1987, 262(19): 9412-9420.
[7] Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends [J]. Journal of Cell Biology, 2013, 200(4): 373-383.
[8] Hosseini M, Khatamianfar S, Hassanian S M, et al. Exosome-encapsulated microRNAs as potential circulating biomarkers in colon cancer [J]. Current Pharmaceutical Design, 2016, DOI: 10.2174/1381612822666161201144634.
[9] Ibrahim A, Marb´an E. Exosomes: fundamental biology and roles in cardiovascular physiology [J]. Annual Review of Physiology, 2016, 78: 67-83.
[10] Andaloussi S E L, M¨ager I, Breakefield X O, et al. Extracellular vesicles: biology and emerging therapeutic opportunities [J]. Nature Reviews: Drug Discovery, 2013, 12(5): 347-357.
[11] Corrado C, Raimondo S, Chiesi A, et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications [J]. International Journal of Molecular Sciences, 2013, 14(3): 5338-5366.
[12] Lázaro-Ibánez E, Sanz-Garcia A, Visakorpi T, et al. Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes [J]. The Prostate, 2014, 74(14): 1379-1390.
[13] Kahlert C, Melo S A, Protopopov A, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer [J]. Journal of Biological Chemistry, 2014, 289(7): 3869-3875.
[14] Sluijter J P, Verhage V, Deddens J C, et al. Microvesicles and exosomes for intracardiac communication [J]. Cardiovascular Research, 2014, 102(2): 302-311.
[15] Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles [J]. Annual Review of Cell and Developmental Biology, 2014, 30: 255-289.
[16] Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts [J]. Seminars in Cancer Biology, 2011, 21(2): 139-146.
[17] Peinado H, Aleckovic M, Lavotshkin S. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET [J]. Nature Medicine, 2012, 18(6): 883-891.
[18] Hoshino A, Costa-Silva B, Shen T L, et al. Tumour exosome integrins determine organotropic metastasis [J]. Nature, 2015, 527(7578): 329-335.

[19] Rana S, Malinowska K, Z¨oller M. Exosomal tumor microRNA modulates premetastatic organ cells [J]. Neoplasia, 2013, 15(3): 281-295.
[20] Zhang L, Zhang S Y, Yao J, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth [J]. Nature, 2015, 527(7576): 100-104.
[21] Cho W C. Molecular diagnostics for monitoring and predicting therapeutic effect in cancer [J]. Expert Review of Molecular Diagnostics, 2011, 11(1): 9-12.
[22] Cho W C. Conquering cancer through discovery research [J]. IUBMB Life, 2010, 62(9): 655-659.
[23] Valadi H, Ekstr¨om K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells [J]. Nature Cell Biology, 2007, 9(6): 654-659.
[24] Ratajczak J, Wysoczynski M, Hayek F, et al. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication [J]. Leukemia, 2006, 20(9): 1487-1495.
[25] Gusachenko O N, Zenkova M A, Vlassov V V. Nucleic acids in exosomes: disease markers and intercellular communication molecules [J]. Biochemistry, 2013, 78(1): 1-7.
[26] Balaj L, Lessard R, Dai L, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences [J]. Nature Communications, 2011, DOI:10.1038/ncomms1180.
[27] Taylor D D, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer [J]. Gynecologic Oncology, 2008, 110(1): 13-21.
[28] Mitchell P S, Parkin R K, Kroh E M, et al. Circulating microRNAs as stable blood-based markers for cancer detection [J]. Proceedings of the National Academy of Sciences, 2008, 105(30): 10513-10518.
[29] Hunter M P, Ismail N, Zhang X, et al. Detection of microRNA expression in human peripheral blood microvesicles [J]. PLoS One, 2008, 3(11): e3694.
[30] Machida T, Tomofuji T, Maruyama T, et al. miR1246 and miR4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer [J]. Oncology Reports, 2016, 36(4):2375-2381.
[31] Baran J, Baj-Krzyworzeka M,Weglarczyk K, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients [J]. Cancer Immunology, Immunotherapy, 2010, 59(6): 841-850.
[32] Rabinowits G, Gerc¸el-Taylor C, Day J M, et al. Exosomal microRNA: a diagnostic marker for lung cancer [J]. Clinical Lung Cancer, 2009, 10(1): 42-46.
[33] Tanaka Y, Kamohara H, Kinoshita K, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma [J]. Cancer, 2013, 119(6): 1159-1167.
[34] Hannafon B N, Trigoso Y D, Calloway C L, et al. Plasma exosome microRNAs are indicative of breast cancer [J]. Breast Cancer Research, 2016, 18(1): 1-14.
[35] Liu C, Eng C, Shen J J, et al. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage Ⅱ and Ⅲcolon cancer [J]. Oncotarget, 2016, 7(46): 76250-76260.
[36] Que R S, Ding G P, Chen J H, et al. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma [J]. World Journal of Surgical Oncology, 2013, DOI: 10.1186/1477-7819-11-219.

[37] Rupp A K, Rupp C, Keller S, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage [J]. Gynecologic Oncology, 2011, 122(2): 437-446.
[38] Moon P G, Lee J E, Cho Y E, et al. Fibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer [J]. Oncotarget, 2016, 7(26): 40189-40199.
[39] Moon P G, Lee J E, Cho Y E, et al. Identification of developmental endothelial locus-1 on circulating extracellular vesicles as a novel biomarker for early breast cancer detection [J]. Clinical Cancer Research, 2016, 22(7): 1757-1766.
[40] Melo S A, Luecke L B, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer [J]. Nature, 2015, 523(7559): 177-182.
[41] Szajnik M, Derbis M, Lach M, et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy [J]. Gynecology & Obstetrics, 2013, DOI: 10.4172/2161-0932. S4-003.
[42] Khan S, Bennit H F, Turay D, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer [J]. BMC Cancer, 2014, DOI: 10.1186/1471-2407-14-176.
[43] Yoshioka Y, Kosaka N, Konishi Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen [J]. Nature Communications, 2014, DOI:10.1038/ncomms4591.
[44] Beckham C J, Olsen J, Yin P N, et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression [J]. The Journal of Urology, 2014, 192(2): 583-592.
[45] Alvarez-Erviti L, Seow Y, Yin H F, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes [J]. Nature Biotechnology, 2011, 29(4): 341-345.
[46] Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells [J]. Molecular Therapy, 2013, 21(1): 185-191.
[47] Shtam T A, Kovalev R A, Varfolomeeva E Y, et al. Exosomes are natural carriers of exogenous siRNA to human cells in vitro [J]. Cell Communication and Signaling, 2013, DOI:10.1186/1478-811X-11-88.
[48] Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phaseⅠclinical trial[J]. Journal of Translational Medicine, 2005, DOI:10.1186/1479-5876-3-10.
[49] Morse M A, Garst J, Osada T, et al. A phaseⅠstudy of dexosome immunotherapy in patients with advanced non-small cell lung cancer [J]. Journal of Translational Medicine, 2005, DOI:10.1186/1479-5876-3-9.
[50] Viaud S, Ploix S, Lapierre V, et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma [J]. Journal of Immunotherapy, 2011, 34(1): 65-75.
[51] Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC [J]. Oncoimmunology, 2016, 5(4):e1071008.
[52] Tian Y H, Li S P, Song J, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy [J]. Biomaterials, 2014, 35(7): 2383-2390.